Findings from THRIVE showed treatment with veligrotug led to statistically significant improvements in the signs and symptoms of TED. Topline data were announced from a phase 3 study evaluating ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...

A 14-year-old otherwise healthy girl developed right eye pain in the periorbital area and proptosis of sudden onset. She was being followed because of mild proptosis. However, the eyelid swelling ...

Powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular pain Heavily pre-treated patient had failed 7 prior regimens including antibody-drug conjugate ...

Acelyrin plans to start a Phase 2b/3 trial of lonigutamab for thyroid eye disease in the second half of 2024. Acelyrin will forego hosting the fiscal year 2023 earnings call and instead announce its ...

-- Teprotumumab is marketed under the brand name TEPEZZA® in the United States-- The primary efficacy endpoint is proptosis response rate at Week 24, measured by the percentage of participants with at ...

"Our study found the asymmetric orbit to have significantly higher muscles volumes compared to its contralateral orbit, thus muscle expansion is one of the likely contributing factors to the ...

Please provide your email address to receive an email when new articles are posted on . WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Andrew G. Lee, MD, discusses ...

What to know about medical treatments, lifestyle adjustments, and more to navigate life with TED.

Please provide your email address to receive an email when new articles are posted on . Glaucoma may be a result of two pressures: IOP and intracranial pressure. When one pressure is high and the ...